Imvax Announces First Patient Dosed in Phase 2b Trial of IGV-001 for Glioblastoma
PHILADELPHIA, PA — Imvax, Inc. recently announced the dosing of the first patient in the company’s randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of IGV-001 in patients with newly …
Imvax Announces First Patient Dosed in Phase 2b Trial of IGV-001 for Glioblastoma Read More